Opinion: Are reasonable restraints on drug price increases doomed by pharma lobbying?
The opposition to an inflation-linked cap on drug price increases is rooted in politics not economic theory, spurred by pharma lobbying to ensure that its profits prevail over the needs…
In a rare but important display of congressional bipartisanship, Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.) have co-sponsored the Prescription Drug Pricing Reduction Act, which includes a meaningful solution to the crisis created by runaway drug price increases. The act would put a cap on drug price increases in Medicare Part D by requiring drug manufacturers to rebate 100% of any price increase that exceeds the rate of inflation.
An shows that the average annual cost of treatment with one of the 214 most widely used branded medications
